Innovation Pharmaceuticals Provides Brilacidin Program Update
Innovation Pharmaceuticals Provides Brilacidin Program Update
WAKEFIELD, MA / ACCESSWIRE / November 18, 2021 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today provided an update on clinical development plans for Brilacidin, the Company's defensin-mimetic drug candidate being evaluated in clinical testing for multiple indications.
馬薩諸塞州韋克菲爾德/ACCESSWIRE/2021年11月18日亞洲網加利福尼亞州聖何塞5月16日電臨牀階段生物製藥公司創新制藥公司(場外交易市場代碼：IPIX)(以下簡稱“公司”)今天提供了Brilacidin的最新臨牀開發計劃。Brilacidin是該公司的防禦素類候選藥物，正在進行多適應症的臨牀測試評估。
The Company remains optimistic about Brilacidin even though the Brilacidin Phase 2 COVID-19 clinical trial did not meet its primary endpoint. There is much still to learn from the trial, with full analysis of the data ongoing. Should deeper analysis yield promising data, the plan is to submit Brilacidin for inclusion in government-sponsored COVID-19 clinical trial platforms.
該公司對Brilacidin仍然持樂觀態度，儘管Brilacidin第二階段新冠肺炎臨牀試驗沒有達到其主要終點。在對數據進行全面分析的過程中，仍有很多東西需要從這項試驗中學到。如果更深入的分析得出有希望的數據，該計劃是將Brilacidin提交給政府支持的新冠肺炎臨牀試驗平臺。
The Company is further encouraged by compassionate use of Brilacidin, which involved the treatment of extremely critically-ill patients who had exhausted all other therapeutic options. Compassionate use cases comprised Brilacidin being administered over a longer duration (up to 10 days) than in the Phase 2 COVID-19 trial (3 and 5 day dosing), with some patients also receiving higher and more frequent dosing (two doses every 24 hours). Patient data is planned to be compiled and evaluated, which may shed additional light on Brilacidin's treatment potential in COVID-19.
該公司進一步受到對Brilacidin的同情使用的鼓舞，這涉及到對用盡所有其他治療選擇的危重患者的治療。同情用例包括使用Brilacidin的時間比第二階段新冠肺炎試驗(3天和5天)長(最多10天)，一些患者還接受更高和更頻繁的劑量(每24小時兩劑)。患者數據計劃進行彙編和評估，這可能會進一步揭示Brilacidin在新冠肺炎的治療潛力。
More broadly, evaluation of Brilacidin's broad-spectrum antiviral properties continues through collaborations with NIH scientists and academic researchers, and may introduce opportunities to study Brilacidin in neglected tropical diseases. The Company plans to announce new findings as they are reported to us.
更廣泛地説，通過與美國國立衞生研究院的科學家和學術研究人員合作，對Brilacidin的廣譜抗病毒特性的評估仍在繼續，並可能為研究Brilacidin在被忽視的熱帶疾病中的作用提供機會。公司計劃在報告給我們的時候宣佈新的發現。
The Company also has not lost sight of the fact that, while Brilacidin for COVID-19 moved to the forefront due to the global pandemic, the focus pre-COVID was on developing Brilacidin for Ulcerative Colitis and Oral Mucositis, both areas of large unmet need with substantial commercial opportunities.
該公司還沒有忽視這樣一個事實，儘管用於新冠肺炎的Brilacidin由於全球流行病而走到了前列，但COVID之前的重點是開發治療潰瘍性結腸炎和口腔粘膜炎的Brilacidin，這兩個領域都有大量未得到滿足的需求，具有巨大的商業機會。
New Inflammatory Bowel Disease (IBD) treatments are sought after given IBD's complex pathogenesis and variability in patient response to any one drug. Oral delivery of Brilacidin to the gut is focused on developing an immediate release, multi-particulate capsule formulation in preparation for clinical testing of Brilacidin in Ulcerative Colitis. Research on Brilacidin stability in the GI tract and its interaction with the gut's microbiome also is underway. Oral Mucositis (OM), a painful side-effect of chemoradiation, similarly represents a tremendous unmet need, as there are no approved drugs for prevention of severe OM. The OM competitive landscape has changed significantly, the result of recent later-stage clinical trial failures by Oragenics, Soligenix and Galera. Development of an optimized Brilacidin oral rinse formulation is in progress, with potential to progress to Phase 3 OM testing in 2022.
鑑於炎症性腸病(IBD)複雜的發病機制和患者對任何一種藥物反應的多變性，人們正在尋求新的炎症性腸病治療方法。口服Brilacidin到腸道的重點是開發一種立即釋放的多顆粒膠囊製劑，為Brilacidin治療潰瘍性結腸炎的臨牀試驗做準備。對Brilacidin在胃腸道中的穩定性及其與腸道微生物羣的相互作用的研究也在進行中。口腔粘膜炎(OM)是放化療的一種痛苦的副作用，同樣也是一個巨大的未得到滿足的需求，因為目前還沒有被批准的預防嚴重OM的藥物。由於Oragenics公司、Soligix公司和Galera公司最近的後期臨牀試驗失敗，OM的競爭格局已經發生了重大變化。一種優化的Brilacidin口腔漱口液配方的開發正在進行中，有可能在2022年進入第三階段OM測試。
The Company believes strongly in Brilacidin's treatment potential and its commercial prospects as a novel drug candidate proven to have antibiotic, anti-inflammatory and antiviral properties. We remain committed to the advancement of our pipeline on multiple fronts and will provide additional updates on pre-clinical and clinical developments as they occur.
該公司堅信Brilacidin的治療潛力及其作為一種被證明具有抗生素、消炎和抗病毒特性的新藥候選藥物的商業前景。我們仍然致力於在多個方面推進我們的渠道，並將在臨牀前和臨牀發展發生時提供更多的最新情況。
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
警報
有關Innovation PharmPharmticals電子郵件警報的註冊信息，請訪問：
Http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases.
關於創新制藥公司
創新制藥公司(IPIX)是一家臨牀階段的生物製藥公司，開發世界級的創新療法組合，解決多種未得到滿足的醫療需求領域，包括炎症性疾病、癌症、傳染病和皮膚病。
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements concerning future drug development plans, statements regarding the antiviral capabilities and therapeutic potential of Brilacidin and its potential impact on SARS-CoV-2 (COVID-19) and other viruses. Other statements regarding future product developments, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are risks related to conducting pre-clinical studies and clinical trials and seeking regulatory and licensing approvals for Brilacidin and Kevetrin in the United States and other jurisdictions, including without limitation that the Company's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere; prior test results may not be replicated in future studies and trials; the Company's need for, and the availability of, substantial capital in the future to fund its operations and research and development, including the amount and timing of the sale of shares of common stock under securities purchase agreements; and the Company's licensee(s) may not successfully complete pre-clinical or clinical testing and the Company will not receive milestone payments. A more complete description of these and other risk factors is included in the Company's filings with the Securities and Exchange Commission. Many of these risks, uncertainties and assumptions are beyond the Company's ability to control or predict. You should not place undue reliance on any forward-looking statements. The forward-looking statements speak only as of the information currently available to the Company on the date they are made, and the Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
前瞻性陳述：本新聞稿包含根據1995年“私人證券訴訟改革法”的安全港條款作出的前瞻性陳述，包括但不限於有關未來藥物開發計劃的陳述、有關Brilacidin的抗病毒能力和治療潛力及其對新冠肺炎(SARS-CoV-2)和其它病毒的潛在影響的陳述。關於未來產品發展的其他陳述，包括關於特定適應症的陳述，以及除歷史事實陳述之外的任何其他陳述。這些陳述涉及風險、不確定因素和假設，可能導致公司的實際結果和經驗與這些前瞻性陳述中表達的預期結果和預期大不相同。在某些情況下，該公司通過使用諸如“預期”、“相信”、“希望”、“估計”、“展望”、“預期”、“計劃”、“打算”、“目標”、“潛在”、“可能”、“建議”等詞語來識別前瞻性陳述。可能導致實際結果與前瞻性陳述中表述的結果大不相同的其他因素包括：在美國和其他司法管轄區進行臨牀前研究和臨牀試驗以及尋求Brilacidin和Kevin etrin的監管和許可批准有關的風險，包括但不限於該公司的化合物可能無法成功完成臨牀前或臨牀測試，或獲得在美國或其他地方銷售和銷售的監管批准；以前的測試結果可能不會在未來的研究和試驗中複製；該公司需要大量藥物以及大量藥物的供應。, 包括根據證券購買協議出售普通股的金額和時間；公司的被許可人可能無法成功完成臨牀前或臨牀測試，公司將不會收到里程碑式的付款。有關這些和其他風險因素的更完整描述包括在該公司提交給證券交易委員會的文件中。其中許多風險、不確定性和假設超出了公司的控制或預測能力。您不應過分依賴任何前瞻性陳述。前瞻性陳述僅代表公司在發佈之日目前掌握的信息，公司沒有義務公開發布對任何此類前瞻性陳述的任何修訂結果，除非適用法律或法規另有要求，否則這些修訂可能反映本新聞稿發佈之日之後的事件或情況，或反映意外事件的發生。(編者注：根據適用法律或法規的要求，這些前瞻性陳述僅代表公司目前掌握的信息，公司沒有義務公開發布任何此類前瞻性陳述的修訂結果，以反映本新聞稿發佈後的事件或情況，或反映意外事件的發生)，除非適用的法律或法規要求。
INVESTOR AND MEDIA CONTACTS
Innovation Pharmaceuticals Inc.
Leo Ehrlich
info@ipharminc.com
投資者和媒體聯繫
創新制藥公司。
利奧·埃爾利希(Leo Ehrlich)
郵箱：info@ipharminc.com
SOURCE: Innovation Pharmaceuticals Inc.
資料來源：創新制藥公司。
譯文內容由第三人軟體翻譯。